Do you think about CDK4/6 inhibitor selection differently in a patient with de novo rather than recurrent metastatic disease?

Not really. Would recommend endocrine therapy with CDK 4/6i for both patients with de novo metastatic disease and those with disease recurrence. The type of endocrine therapy might vary though - would consider Fulvestrant as endocrine therapy partner for a patient who has disease recurrence on adjuv...

No. The selection of first line CDK4/6 inhibitors is dependent on different things including overall survival data, patient characteristics, and other factors elaborated in the answer to the next question. Exploratory subgroup analysis of MONALEESA-2 showed OS benefit in various subgroups consistent...